Literature DB >> 26024696

When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?

William M Mendenhall1, Primož Strojan, Avraham Eisbruch, Robert Smee, Alessandra Rinaldo, Alfio Ferlito.   

Abstract

Entities:  

Year:  2015        PMID： 26024696     DOI： 10.1007/s00405-015-3660-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  33 in total

1.  Definitive radiotherapy for squamous cell carcinoma of the base of tongue.

Authors:  William M Mendenhall; Christopher G Morris; Robert J Amdur; Russell W Hinerman; John W Werning; Douglas B Villaret
Journal:  Am J Clin Oncol       Date:  2006-02       Impact factor: 2.339

Review 2.  Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era.

Authors:  Anne W M Lee; Wai Tong Ng; Lucy L K Chan; Wai Man Hung; Connie C C Chan; Henry C K Sze; Oscar S H Chan; Amy T Y Chang; Rebecca M W Yeung
Journal:  Radiother Oncol       Date:  2014-03-11       Impact factor: 6.280

3.  Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.

Authors:  Kent W Mouw; Abhishek A Solanki; Kerstin M Stenson; Mary Ellyn Witt; Elizabeth A Blair; Ezra E W Cohen; Everett E Vokes; Marcy List; Daniel J Haraf; Joseph K Salama
Journal:  Oral Oncol       Date:  2012-05-22       Impact factor: 5.337

4.  Definitive radiotherapy for T1-2 hypopharyngeal cancer: a single-institution experience.

Authors:  Aya Nakajima; Kinji Nishiyama; Masahiro Morimoto; Satoaki Nakamura; Osamu Suzuki; Yoshifumi Kawaguchi; Ken Miyagi; Takashi Fujii; Kunitoshi Yoshino
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

5.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.

Authors:  Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

6.  Current treatment of T1N0 squamous cell carcinoma of the glottic larynx.

Authors:  William M Mendenhall; Robert P Takes; Jatin P Shah; Patrick J Bradley; Jonathan J Beitler; Primož Strojan; Carlos Suárez; Juan P Rodrigo; Nabil F Saba; Alessandra Rinaldo; Jochen A Werner; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-08       Impact factor: 2.503

7.  Definitive radiotherapy for T1-T2 squamous cell carcinoma of pyriform sinus.

Authors:  Anna Rabbani; Robert J Amdur; Anthony A Mancuso; John W Werning; Jessica Kirwan; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

8.  Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy.

Authors:  Leena-Maija Aaltonen; Noora Rautiainen; Jaana Sellman; Kauko Saarilahti; Antti Mäkitie; Heikki Rihkanen; Jussi Laranne; Leenamaija Kleemola; Tuija Wigren; Eeva Sala; Paula Lindholm; Reidar Grenman; Heikki Joensuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

9.  Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.

Authors:  William M Mendenhall; Christopher G Morris; Robert J Amdur; Russell W Hinerman; Anthony A Mancuso
Journal:  Head Neck       Date:  2003-07       Impact factor: 3.147

10.  Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.

Authors:  Jun Won Kim; Mi Sun Kim; Se-Heon Kim; Joo Hang Kim; Chang Geol Lee; Gwi Eon Kim; Ki Chang Keum
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.